Our development pipeline

Reinvesting our profit to discover new medicines

At Servier, major investment in R&D (Close to 20% of revenue from brand-name medicines) creates a promising pipeline of innovative projects targeting illnesses with significant unmet medical needs. Our pipeline reflects our ambition to concentrate on the quality and potential of R&D projects, half of which have the potential to become “first-in-class” medicines.

In January 2026, it comprised 62 projects, 41 of which in clinical development and 21 research projects.